Drag from side to side.
Drag from side to side.
Type of stroke | Nelonemdaz | NMDA antagonists | Antioxidants | |
---|---|---|---|---|
Treatment Time Window in vivo | Severe tMCAO | 8 hour | Less than 1 hour | 2-4 hour |
Mild tMCAO | 48 hour | ND (Not Determined) |
||
Permanent MCAO | 4 hour | |||
Forebrain ischemia | 24 hour | |||
Safety in human | Phase I for Healthy Subjects Phase II for Stroke |
*Safe up to 6,000mg(IV) | SAE at target doses |
SAE at target doses (e.g. edaravone) |
Two Phase I Studies 165 subjects in US & China Two Phase II Studies 447 patients in China & SK |
||||
Efficacy in human | Ischemic Stroke alone | ND | All failed | All failed except edaravone in Japan |
Ischemic stroke with thrombolytics | Beneficial effects in PII (N=238) | |||
PIII ongoing | ||||
Ischemic stroke with endovascular thrombectomy | Promising beneficial effects in PII SOINC (N=209) | Nerinetide little beneficial effects in PIII (N=1105) | ND | |
PIII RODIN ongoing | ||||
Cardiac Arrest with ROSC | PII AWAKE (N=78 at present) | ND | ND |
Journal of Cerebral Blood Flow and Metabolism. 2007
DownloadJournal of Neurochemistry. 2009
DownloadDrug News & Perspectives. 2010
DownloadActa Neuropathol. 2010
DownloadJournal of Neurotrauma. 2010
DownloadExperimental and Molecular Medicine. 2011
DownloadToxicology in Vitro. 2013
DownloadArchives of Phamacal Research. 2013
DownloadTrials. 2018
DownloadTrials. 2022
DownloadStroke. 2022
Download